Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Cocaine Dependence Clinical Trial

Official title:

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00913484
• Other study ID #: 1R01DA012979
• Secondary ID: 1R01DA012979
• Status: Completed
• Phase: Phase 2
• Start date: October 2000
• Est. completion date: February 2004

Study information

• Verified date: November 2020
• Source: Yale University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators are proposing a placebo-controlled clinical trial to evaluate the efficacy and potential mechanisms of action of disulfiram (versus placebo) for treating cocaine abuse in subjects with concurrent opiate dependence and cocaine abuse or dependence maintained on buprenorphine/naloxone combination.

Description:

The Specific Aims and hypotheses for the proposed study are as follows: 1. To compare the efficacy of disulfiram versus placebo for the treatment of buprenorphine maintained patients with concurrent opioid and cocaine dependence. Study hypothesis 1 is that disulfiram is superior to placebo. 2. To evaluate whether dopamine-B-hydroxylase (DBH) genotypes associated with high, intermediate or low enzyme activity predict responses to disulfiram treatment of cocaine use in buprenorphine treated subjects. Study hypothesis 2 is that disulfiram efficacy is higher in subjects with low DBH compared to subjects with high DBH. 3. To explore whether baseline measures of alcohol use predict response to disulfiram. Study Hypothesis 3 is that the effects of disulfiram on cocaine use are independent of the severity of baseline alcohol use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 177
• Est. completion date: February 2004
• Est. primary completion date: February 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• English speaking adults ages 18 - 45.
• Meeting FDA criteria for agonist maintenance treatment and DSM-IV criteria for opioid dependence and cocaine dependence or abuse as assessed by SCID interview and documented by opioid positive and cocaine positive urine toxicology testing.
• Women of childbearing age will be included provided they agree to adequate contraception and to monthly pregnancy testing during the course of the study.

Exclusion Criteria:

• Current physiologic dependence on benzodiazepines or alcohol, unless first detoxified. Subjects who use/abuse alcohol will be included but will be cautioned about alcohol use during the study because of the possibility of an alcohol-disulfiram reaction.
• Use of the antibiotic agents metronidazole or clotrimazole, which have disulfiram-like effects in combination with alcohol.
• Presence of significant cardiovascular, renal, hepatic or neurologic illness. Subjects with markedly abnormal liver function tests (i.e., AST of ALT > 3X normal) will also be excluded.
• Presence of any of the following cardiovascular risk factors:
• age > 45 years
• history of cocaine-related chest pain
• systolic blood pressure > 140 or diastolic blood pressure > 90
• evidence of ischemia or past myocardial infarction on EKG
• significant family history of risk (first degree relative with myocardial infarction prior to age 60)
• elevated cholesterol (> 300 mg/dl), elevated LDL (> 170 mg/dl) or low HDL (< 20 mg/dl)
• Maintenance on methadone at doses greater than 30mg daily. Admittance to the study will only be offered to individuals who have been maintained on 30 mg of methadone or less daily for seven days prior to entering the study.
• Current suicide or homicide risk or current psychotic disorder.
• Inability to read or understand the symptom checklists.

Related Conditions & MeSH terms

• Cocaine Dependence
• Cocaine-Related Disorders
• Opioid Dependency

Intervention

Drug:
• Disulfiram
Disulfiram 250 mg per day
• Placebo
Placebo daily

Locations

Country	Name	City	State
United States	The APT Foundation MRU	New Haven	Connecticut
United States	Yale University School of Medicine	New Haven	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Yale University	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cocaine abstinence		12 weeks
Secondary	Opioid abstinence		12 weeks